Proteasome inhibitors in cancer therapy: Treatment regimen and peripheral neuropathy as a side effect

Article ID	Journal	Published Year	Pages	File Type
5502200	Free Radical Biology and Medicine	2017	46 Pages	PDF

Abstract

Recent studies focus on peripheral neuropathy as the primary side effect of proteasome inhibitors. Therefore, it is important to delineate the underlying mechanisms of peripheral neuropathy and develop new inhibitors according to obtained data. This review will detail the role of proteasome inhibition in cancer therapy and development of peripheral neuropathy as a side effect. Additionally, new approaches to prevent treatment-limiting side effects will be discussed in order to help researchers in developing effective strategies to overcome side effects of proteasome inhibitors.

Keywords

MMP TGF-β TNF FDA XIAP MDR1 CIPN TLR AP-1 N-methyl-d-aspartate NMDA APEX PARP-1 DRG natural killer Mdm2 adenosine-5′-triphosphate ATP angiopoietin AIF Summit Ang interleukin Bortezomib Crest Toll-like receptor World Health Organization Food and Drug Administration chemotherapy-induced peripheral neuropathy Chemotherapy apoptosis inducing factor tumor growth factor-β Vascular endothelial growth factor Vascular Endothelial Growth Factor (VEGF)tumor necrosis factor TRAIL TNF-related apoptosis inducing ligand matrix metalloproteinase Mouse double minute 2 Multiple myeloma Neuropathy Proteasome X-linked Inhibitor of Apoptosis Protein retinoblastoma protein activator protein-1 multidrug resistance protein 1 Carfilzomib WHO dorsal root ganglia UPS